Intellia Therapeutics (NTLA) Net Cash Flow (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Net Cash Flow of -$17.5 million for Q1 2026, up 68.01% year-over-year from -$10.4 million in Q1 2025, and up 56.08% quarter-over-quarter from -$39.8 million in Q4 2025.
Intellia Therapeutics (NTLA) Net Cash Flow (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Net Cash Flow for 12 consecutive years, with -$17.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 68.01% year-over-year to -$17.5 million; the TTM figure through Mar 2026 stood at $1.9 million (up 105.12% YoY), while the FY2025 annual figure was -$35.2 million, up 6.25% from the prior year.
- Net Cash Flow advanced to -$17.5 million in Q1 2026 per NTLA's latest filing, from -$39.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $385.7 million in Q4 2022 and bottomed at -$229.4 million in Q1 2023.
- Historically, Net Cash Flow has averaged $1.4 million across 5 years, with a median of -$6.9 million in 2022.
- Annual changes were most pronounced in 2023 — Net Cash Flow sank 1629.85% — and 2025, when it jumped 459.45%.
- Intellia Therapeutics' Net Cash Flow stood at $385.7 million in 2022, then tumbled by 84.61% to $59.4 million in 2023, then rose by 15.7% to $68.7 million in 2024, then plunged by 157.91% to -$39.8 million in 2025, then surged by 56.08% to -$17.5 million in 2026.
- Business Quant data shows NTLA's Net Cash Flow at -$17.5 million in Q1 2026, -$39.8 million in Q4 2025, and $37.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -28.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.57 Mn |
| Jun 30, 2026 | -28.57 Mn |
| Mar 31, 2026 | -17.47 Mn |
| Mar 31, 2026 | -17.47 Mn |
| Dec 31, 2025 | -39.77 Mn |
| Dec 31, 2025 | -39.77 Mn |
| Sep 30, 2025 | 37.22 Mn |
| Sep 30, 2025 | 37.22 Mn |
| Jun 30, 2025 | 21.94 Mn |
| Jun 30, 2025 | 21.94 Mn |
| Mar 31, 2025 | -54.60 Mn |
| Mar 31, 2025 | -54.60 Mn |
| Dec 31, 2024 | 68.69 Mn |
| Dec 31, 2024 | 68.69 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -41.13 Mn |
| Jun 30, 2024 | -41.13 Mn |
| Mar 31, 2024 | -54.77 Mn |
| Mar 31, 2024 | -54.77 Mn |